The purpose of this study is to see if using a handheld ultrasound to measure a baby?s growth is the same as using a measuring tape to measure a mother?s fundal height. A woman?s fundal height is measured from the top of her uterus (where the baby is growing) to the area below her belly button where the pubic bone begins. Both of these methods are used a lot to measure how babies are growing but doctors would like to know if both of the ways come up with the same results. The handheld ultrasound device that is used in this study has been approved for use by the United States Food and Drug Administration (FDA).
The purpose of this study is to compare body fat distribution in neonates exposed to antiretroviral (ARV) therapy for the prevention of maternal to child transmission (MTCT) of HIV versus ARV naive neonates born at a similar gestational age to HIV-negative women. As a secondary analysis, we will examine the differences in body fat distribution among ARV-exposed neonates comparing PI-exposed versus non-PI exposed.
This study will look at abnormal blood circulation changes especially in the arteries supplying blood to the uterus (where the baby develops) using Doppler ultrasound. The research team will perform Doppler ultrasound scans at an early pregnancy scan and during the fetal anatomy scan to understand blood flow changes when subjects are lying on their back versus when they are tilted to their left and also when they bear down for 10 seconds.
The purpose of this study is to evaluate whether the AmniSure ROM (Rupture of [fetal] Membrane) test read by personnel in the subject?s room gives the same result as the AmniSure ROM test read in a laboratory. Researchers will then look to see how both results compare to the results of three standard test methods to detect ruptured (broken) fetal membranes (rupture of the sac where the fetus develops). These standard tests are called nitrazine, ferning, and pooling.
The purpose of this study is to study cells that are found in the cord blood of pregnant women to see if they might be helpful in treating certain types of infections. This type of research is still in the very early stage, so we will do this by taking some of the special cells found in cord blood and injecting them into mice and studying them.
This is a multicenter, observational study.
This research study will test whether the methods being developed for the detection of fetal abnormality from samples of maternal blood can be used in the laboratory and employed in clinical practice
The purpose of this study is to determine if exposure to certain chemicals by the mother affects the size of your baby’s genitals.
At the time of enrollment, a maternal urine sample will be collected and tested for bisphenol A and phthalate metabolites, organic compounds that can be found in your urine. This urine sample will be about 80 ml or 5 tablespoons. A blood sample will also be collected at enrollment. This blood sample will be about 30 ml or 2 tablespoons. There is very important information that can be gained by collecting your blood sample and you contribution to this study would be greatly appreciated. However, if you choose not to supply a blood sample, you can still participate in the other portions of the study. If you do not want to participate in the blood collection portion of the study, please notify the study staff. You will also be asked to complete a questionnaire that will allow Dr. Unal and the research staff to have a better idea of your everyday life and your contact with plastic. The questionnaire will be given to you by the study staff at the time of enrollment in the study.
Regardless of where you plan to deliver your baby, if it is determined that you are having a boy during your fetal anatomic ultrasound, we will measure the length and width of your baby's penis. The measurements will be taken using the high resolution picture created by the ultrasound. If it is determined that you are having a girl no measurements will be taken during the ultrasound.
During your scheduled office vist between 24 and 32 weeks gestation, you will be asked to provide a 2nd urine sample. This urine sample will be about 80 ml or 5 tablespoons.
If you plan to deliver at MUSC, then the following procedures will take place after delivery:
At the time of delivery appproximately 15 ml or 1 tablespoon of fetal cord blood will be collected; this does not involve a needle-stick to the baby as the blood is collected directly from the umbilical cord after the placenta is delivered. In addition, approximately 30 ml or 2 tablespoons (two extra tubes of blood) will be collected at the time of IV placement. This blood sample will not involve a needle-stick. Also at the time of delivery an additional maternal urine sample (about 80 ml or 5 tablespoons) will be taken. These samples will be stored for later analysis of bisphenol A, phthalate metabolites, and androgens, which are male hormones.
Genital measurements will also be taken of your baby.
With current standard of care practice, Implanon, a long acting reversible contraceptive measure is placed at the 6 week post partum visit. This study is examining whether or not it is more beneficial to have the Implanon placed prior to leaving the hospital. If you are between 15-21 years of age and are considering using Implanon as your post partum birth control, then you may be eligible to qualify. Study participants have a 50% chance of having Implanon placed prior to leaving the hospital and must commit to completing a baseline questionnaire at enrollment and three follow-up questionnaires by phone at 3,6, and 12 months after delivery. Compensation is available. Please contact the coordinator for more details.